267404-26-2

Upstream product

• 558437-80-2 benzoic acid 4-(tert-butoxycarbonylamino-methyl)-4-phenyl-cyclohexyl ester 
• 267405-19-6 (4-hydroxy-1-phenyl-cyclohexylmethyl)-carbamic acid tert-butyl ester 
• 267405-17-4 (4-hydroxy-1-phenyl-cyclohexylmethyl)-carbamic acid tert-butyl ester 
• 603138-40-5 4-aminomethyl-4-phenyl-cyclohexanol 
• 267405-16-3 cis-1-hydroxy-4-phenyl-4-(aminomethyl)cyclohexane 
• 38289-22-4 cis-4-hydroxy-1-phenylcyclohexanecarbonitrile 
• 21615-34-9 2-Methoxybenzoyl chloride 
• 25115-74-6 4-cyano-4-phenylcyclohexanone 
• 124-63-0 methanesulfonyl chloride 
• 267402-72-2 trans-1-hydroxy-4-phenyl-4-(3-(2-methoxyphenyl)-3-oxo-2-azaprop-1-yl)cyclohexane 

Downstream Products

• 267403-38-3 cis-1-amino-4-phenyl-4-(3-(2-methoxyphenyl)-3-oxo-2-azaprop-1-yl)cyclohexane 
• 267403-39-4 {4-[(2-methoxy-benzoylamino)-methyl]-4-phenyl-cyclohexyl}-carbamic acid 4-nitro-phenyl ester 
• 267404-58-0 4-phenyl-4-(3-(2-methoxyphenyl)-3-oxo-2-azaprop-1-yl)-cyclohex-1-ene 
• 267405-12-9 cis-1-azido-4-phenyl-4-(3-(2-methoxyphenyl)-3-oxo-2-azaprop-1-yl)cyclohexane 

Relevant academic research and scientific papers

Benzamide derivatives as blockers of Kv1.3 ion channel

The voltage-gated potassium channel, Kv1.3, is present in human T-lymphocytes. Blockade of Kv1.3 results in T-cell depolarization, inhibition of T-cell activation, and attenuation of immune responses in vivo. A class of benzamide Kv1.3 channel inhibitors

Carbocyclic potassium channel inhibitors

The present invention relates to a class of carbocyclic compounds of Formula I that are useful as potassium channel inhibitors to treat autoimmune disorders, cardiac arrhythmias, and the like.